Skip to Content
Global News Select

Boston Scientific 4Q Profit Sinks as Sales Decline

By Matt Grossman


Boston Scientific Corp. on Wednesday posted a smaller fourth-quarter profit to finish 2020, as sales from its cardiovascular and medical-devices segments declined year over year.

The Marlborough, Mass.-based medical-products company logged a profit of 10 cents a share, compared with $2.83 a share a year earlier. Net income available to common stockholders was $138 million, down from $4 billion in the prior-year period, it said.

Boston Scientific's adjusted profit was 23 cents a share, the company said.

The company posted revenue of $2.71 billion, down from $2.91 billion.

Medical-surgical sales climbed 1.5% year over year to $892 million, but the company's other divisions lost ground. Cardiovascular sales declined 12% year over year and rhythm-and-neuro sales sank by 6.1%. The medical-devices segment was also down 6.1%, it said.


Write to Matt Grossman at


(END) Dow Jones Newswires

February 03, 2021 07:11 ET (12:11 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.